Carlos Torres Carvalho
Carlos Torres Carvalho publishes mostly in Oncology, Surgery and Pulmonary and Respiratory Medicine, on topics such as Colorectal Cancer Treatments and Studies, Colorectal Cancer Surgical Treatments and Hepatocellular Carcinoma Treatment and Prognosis.
- World rank
- #855,769 of 7,710,434 ranked researchers
- Rank in Portugal
- #3,233 of 41,760
- Works
- 75
- Citations
- 3.1k
- Citations per work
- 40.8
What does Carlos Torres Carvalho research?
Carlos Torres Carvalho's work is mostly in Medicine (68%), Biochemistry, Genetics and Molecular Biology (5%), Immunology and Microbiology (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences5167.7%
- Medicine5167.7%
- Everything else1823.9%
- Life Sciences68.4%
- 1Oncology35% of their works
- 2Surgery18% of their works
- 3Pulmonary and Respiratory Medicine8% of their works
- 4Hepatology7% of their works
- 5Cancer Research5% of their works
- 6Immunology4% of their works
Research topics
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal and Anal Carcinomas
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
Which keywords describe Carlos Torres Carvalho's research?
The keywords of their largest research topics: Chemotherapy, Clinical Practice Guidelines, Neoadjuvant Therapy, Cetuximab, KRAS Mutations, Preoperative Chemoradiotherapy, Rectal Cancer and Hepatocellular Carcinoma.
- PD-1 and PD-L1
- Gastric Cancer
- Surgical Complications
- Cholangiocarcinoma
- Chemoradiation
- Tumor Microenvironment
- Hepatocellular Carcinoma
- Preoperative Chemoradiotherapy
- Cetuximab
- Clinical Practice Guidelines
- Chemotherapy
- Neoadjuvant Therapy
- KRAS Mutations
- Rectal Cancer
- Liver Cancer
- Anal Cancer
- Biliary Tract Cancer
- Pancreatic Cancer
- Endoscopic Resection
- Immune Checkpoint Blockade
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 20 words, with their numbers
- Chemotherapy504 topics
- Clinical Practice Guidelines393 topics
- Neoadjuvant Therapy282 topics
- Cetuximab241 topic
- KRAS Mutations241 topic
- Preoperative Chemoradiotherapy191 topic
- Rectal Cancer191 topic
- Hepatocellular Carcinoma151 topic
- Liver Cancer151 topic
- Tumor Microenvironment142 topics
- Anal Cancer121 topic
- Chemoradiation121 topic
- Biliary Tract Cancer111 topic
- Cholangiocarcinoma111 topic
- Pancreatic Cancer91 topic
- Surgical Complications91 topic
- Endoscopic Resection51 topic
- Gastric Cancer51 topic
- Immune Checkpoint Blockade51 topic
- PD-1 and PD-L151 topic
Where does Carlos Torres Carvalho work?
Carlos Torres Carvalho's main affiliation in the publication record is Champalimaud Foundation, Portugal.
How many publications and citations does Carlos Torres Carvalho have?
OpenAlex counts 75 works and 3,057 citations for Carlos Torres Carvalho, an h-index of 20, ranking #855,769 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Carlos Torres Carvalho. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.